<DOC>
	<DOCNO>NCT00492648</DOCNO>
	<brief_summary>The safety immunogenicity GSK324332A vaccine evaluate Month 12 post-vaccination primary study . In extension study present , persistence cellular humoral immune response evaluate 30 42 month first vaccination young elderly adult receive GSK324332A vaccine . This protocol post deal objective &amp; outcome measure extension phase Months 30 42 . No new recruitment do extension phase primary study . No vaccine administer phase study .</brief_summary>
	<brief_title>Month 30 &amp; 42 Extension Studies CRD-004 Primary Study</brief_title>
	<detailed_description>All subject extension phase study previously vaccinate investigational herpes zoster vaccine GSK1437173A . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study ; Subjects successfully complete primary study receive Varilrix primary study ; Written inform consent obtain subject ; Free obvious health problem establish medical history clinical examination enter study . Use investigational nonregistered product ( drug vaccine ) within 1 month precede study start , plan use study period ; Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within three month prior first study procedure , include corticosteroid , except inhaled topical steroid allow ; Administration plan administration vaccine foreseen study protocol within 2 week first study procedure , exception Influenza vaccine , administer 1 week precede first study procedure ; Previous vaccination HZ , except study vaccine administer primary study ; History HZ ( shingle ) ; Any confirm suspected immunosuppressive immunodeficient condition base medical history physical examination ; Administration immunoglobulins and/or blood product within 3 month precede first study procedure plan administration study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>GSK Biologicals</keyword>
	<keyword>Varicella Zoster Virus ( VZV )</keyword>
	<keyword>Intracellular cytokine staining ( ICS )</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Cell mediate immunity ( CMI )</keyword>
	<keyword>Herpes Zoster ( HZ )</keyword>
	<keyword>Shingles</keyword>
</DOC>